person · Reporting owner

Agopyan Nadia

Disclosed activity across 1 company

Tapewire entity: 116262
SEC CIK: 0001784758

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Marker Therapeutics, Inc.MRKR · Entity 7609	SVP, Regulatory Affairs	February 27, 2023	March 01, 2023

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Marker Therapeutics, Inc.

Report date February 27, 2023 · Filed March 01, 2023

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.14 · Expires 2033-02-27	Direct	34,154	Reported balance After 2023-02-27 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2023-02-27 · Grant · Acquired 34,154 · Balance 34,154 F1: This option vests in equal monthly installments over a four year period commencing on March 27, 2023 subject to the continued service by the Reporting Person to the Issuer as of the applicable vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: This option vests in equal monthly installments over a four year period commencing on March 27, 2023 subject to the continued service by the Reporting Person to the Issuer as of the applicable vesting date.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
February 27, 2023 Filed Mar 1, 2023 21:47 UTC	Marker Therapeutics, Inc. MRKR · Entity 7609	GrantEmployee Stock Option (right to buy) · Derivative	34,154	$0.00 Strike: $2.14	$0.00	Disclosure SEC source: 0001209191-23-014155 · doc4.xml · derivative · entry 1 Agopyan Nadia · CIK 0001784758 · SVP, Regulatory Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,154 Underlying: Common Stock · 34,154 shares Expires 2033-02-27 F1 · derivative.exercise_date: This option vests in equal monthly installments over a four year period commencing on March 27, 2023 subject to the continued service by the Reporting Person to the Issuer as of the applicable vesting date. Read SEC document
February 17, 2022 Filed Feb 22, 2022 22:01 UTC	Marker Therapeutics, Inc. MRKR · Entity 7609	GrantEmployee Stock Option (right to buy) · Derivative	40,000	$0.00 Strike: $0.46	$0.00	Disclosure SEC source: 0001209191-22-011745 · doc4.xml · derivative · entry 1 Agopyan Nadia · CIK 0001784758 · VP, Regulatory Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2032-02-17 F1 · derivative.exercise_date: This option vests in equal monthly installments over a four year period commencing on March 17, 2022 subject to the continued service by the Reporting Person to the Issuer as of the applicable vesting date. Read SEC document
February 10, 2021 Filed Feb 12, 2021 22:21 UTC	Marker Therapeutics, Inc. MRKR · Entity 7609	GrantEmployee Stock Option (right to buy) · Derivative	40,000	$0.00 Strike: $3.29	$0.00	Disclosure SEC source: 0001209191-21-010256 · doc4.xml · derivative · entry 1 Agopyan Nadia · CIK 0001784758 · VP, Regulatory Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2031-02-10 F1 · derivative.exercise_date: This option vests in equal monthly installments over a four year period commencing on March 10, 2021 subject to the continued service by the Reporting Person to the Issuer as of the applicable vesting date. Read SEC document
March 10, 2020 Filed Mar 12, 2020 20:35 UTC	Marker Therapeutics, Inc. MRKR · Entity 7609	GrantEmployee Stock Option (Right to Buy) · Derivative	32,700	$0.00 Strike: $2.12	$0.00	Disclosure SEC source: 0001209191-20-018524 · doc4.xml · derivative · entry 2 Agopyan Nadia · CIK 0001784758 · VP, Regulatory Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,700 Underlying: Common Stock · 32,700 shares Expires 2030-03-10 F2 · derivative.exercise_date: This option vests in equal monthly installments over a four year period commencing on April 10, 2020 subject to the continued service by the Reporting Person to the Issuer as of the applicable vesting date. Read SEC document
March 10, 2020 Filed Mar 12, 2020 20:35 UTC	Marker Therapeutics, Inc. MRKR · Entity 7609	GrantEmployee Stock Option (Right to Buy) · Derivative	7,300	$0.00 Strike: $2.12	$0.00	Disclosure SEC source: 0001209191-20-018524 · doc4.xml · derivative · entry 1 Agopyan Nadia · CIK 0001784758 · VP, Regulatory Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,300 Underlying: Common Stock · 7,300 shares Expires 2030-03-10 F1 · derivative.exercise_date: Represents a bonus for 2019 performance granted under the Company's 2014 Omnibus Stock Ownership Plan. This option vests in equal monthly installments over a four year period commencing on April 10, 2020 subject to the continued service by the Reporting Person to the Issuer as of the applicable vesting date. Read SEC document
August 15, 2019 Filed Aug 19, 2019 21:09 UTC	Marker Therapeutics, Inc. MRKR · Entity 7609	GrantEmployee Stock Option (right to buy) · Derivative	200,000	$0.00 Strike: $4.80	$0.00	Disclosure SEC source: 0001209191-19-046630 · doc4.xml · derivative · entry 1 Agopyan Nadia · CIK 0001784758 · VP, Regulatory Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2029-08-15 F1 · derivative.exercise_date: Twenty-five percent (25%) of the shares underlying the Option shall vest on August 15, 2020, with the balance of the shares vesting in thirty-six (36) equal monthly installments thereafter. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.